4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy candidate using the AAVnerGene Inc. (AAVnerGene) platform technology. As previously announced, AAVnerGene is an innovation-driven biotech renowned for its transformative technologies in adeno-associated viruses (AAV) manufacturing and tissue-targeted delivery. KLOTHO is a biotechnology company focused on the development of groundbreaking, disease-modifying cell and gene therapies using a human gene and protein derived from its patented form of the "anti-aging" Klotho gene.

Company to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK, July 25, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho") announced that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity. In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies th

Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK, July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) (the "Company" or "Klotho") announced today that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity. In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies that compleme

NEW YORK, July 22, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), announced that it is partnering with AAVnerGene Inc. (AAVnerGene), a Rockville, MD-based innovation-driven biotech renowned for its transformative technologies in AAV manufacturing and tissue-targeted delivery.  Dr. Joseph Sinkule, the CEO of KLTO stated "we announced previously that we have been looking for a more efficient, 'next-generation' method to manufacture several of our patented gene therapy candidates, and the two platform technologies offered by AAVnerGene will catapult our product ca

Klotho Neurosciences Maintains Listing on the NASDAQ NEW YORK, July 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that it had received a notification letter from The NASDAQ Stock Market LLC confirming that the Company has regained compliance with the minimum $1.00 bid price under NASDAQ Listing Rule 5550(a)(2), and the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1).

NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's novel secreted-Klotho (s-KL) promoter, gene and delivery system (KLTO-202, or s-KL-AAV.myo) for the treatment of ALS. The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseas

NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ("UAB") including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene an

NEW YORK, June 24, 2025 /PRNewswire/ -- Klotho Neuroscience, Inc. (NASDAQ: KLTO), a US-based biogenetics company developing cell and gene- based treatments to address neurological conditions, including ALS, Alzheimer's Disease (AD) and Parkinson's Disease (PD), has announced that it is partnering with Drs. Makoto Suzuki, Craig and Bradley Willcox, Richard Allsopp, and Michio Shimabukuro of the Okinawa Research Center for Longevity Science (ORCLS), as part of its research program on Okinawa, Japan, where a comparatively high number people live extremely long and healthy lives, many reaching 100 years and more.

Key highlights of the announcement include: Elimination of Future Dilution: The Company will no longer be required to issue new common stock to SkyBell, which would have resulted in SkyBell owning 90% of the Company—substantially diluting existing shareholders.No Liability: Neither Klotho nor SkyBell will incur any liability as a result of the termination.Refocused Strategy: The termination enables Klotho to remain focused on its core assets and to allocate resources and capital toward advancing its primary therapeutic and longevity programs. These include pipeline candidates targeting neurodegenerative and other age-related diseases.NEW YORK, June 18, 2025 /PRNewswire/ -- Klotho Neuroscienc

Highlights: Over $11 Million Raised: Proceeds were generated through the exercise of existing warrants. Chardan Capital Markets was the exclusive financial advisor in connection with public warrant exercises.Update on NASDAQ Compliance: Klotho believes it now exceeds the stockholders' equity thresholds required to remain in compliance with NASDAQ listing requirements.Zero Debt: Klotho has fully extinguished all outstanding debt, resulting in a debt-free balance sheet.NEW YORK, June 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company, today announced that over the course of the last ten days, it raised over $11 million in funding through the ex

10-Q - Klotho Neurosciences, Inc. (0001907223) (Filer)

NT 10-Q - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

424B5 - Klotho Neurosciences, Inc. (0001907223) (Filer)

424B3 - Klotho Neurosciences, Inc. (0001907223) (Filer)

424B3 - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K/A - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's and Parkinson's disease is proud to announce the appointment of Dr. Merit Cudkowicz, MD, MSc, to its Scientific Advisory Board (SAB). Dr. Cudkowicz is the Chair of Neurology at MGH, Director of the Sean M. Healey & AMG Center for ALS, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a leading clinician in promoting and devising more efficient methods for the development of thera

NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer's, and Parkinson's, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic partnerships. During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over $12 billion in revenue. Prior to that role, he ser

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the Klotho gene, often referred to as the "anti-aging gene." While conducting groundbreaking research at the National Institute of Neuroscience in Tokyo, Dr. Kuro-o and his team identified the Klotho gene while studying mice engineered to overexpress a gene linked to premature aging. Th

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosciences, welcomed Moriarty to the leadership team: "We are thrilled to have Peter join Klotho Neurosciences as COO. His extensive experience across the pharmaceutical industry, both in the U.S. and globally, will be instrumental as we move forward. Peter has a remarkable track record, including leadership roles at